AlphaCentric Advisors’s Jazz Pharmaceuticals JAZZ Stock Holding History

AlphaCentric Advisors’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$871K	Buy	3,613 +52	+1%	+$11.4K	0.74%	32
2026 Q1	$673K	Buy	3,561 +193	+6%	+$33.7K	0.67%	38
2025 Q4	$573K	Buy	+3,368	New	+$516K	0.57%	55
2024 Q4	–	Sell	-15,500	Closed	-$1.73M	–	251
2024 Q3	$1.73M	Buy	15,500 +4,500	+41%	+$493K	1.28%	24
2024 Q2	$1.17M	Buy	11,000 +2,500	+29%	+$275K	0.86%	40
2024 Q1	$1.02M	Sell	8,500 -2,000	-19%	-$245K	0.62%	61
2023 Q4	$1.29M	Sell	10,500 -16,000	-60%	-$2M	0.87%	43
2023 Q3	$3.43M	Sell	26,500 -14,250	-35%	-$1.9M	1.95%	7
2023 Q2	$5.05M	Buy	40,750 +33,750	+482%	+$4.54M	2.8%	1
2023 Q1	$1.02M	Buy	7,000 +3,500	+100%	+$518K	0.71%	49
2022 Q4	$558K	Hold	3,500	–	–	0.55%	66
2022 Q3	$467K	Buy	+3,500	New	+$532K	0.48%	61
2021 Q4	$1.27M	Buy	+10,000	New	+$1.31M	0.37%	19
2020 Q4	–	Sell	-350	Closed	-$50K	–	219
2020 Q3	$50K	Sell	350 -275	-44%	-$34.1K	0.02%	107
2020 Q2	$69K	Buy	+625	New	+$69.1K	0.04%	70

Other funds holding JAZZ

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

AlphaCentric Advisors's JAZZ Position: Q2 2026 in Review

AlphaCentric Advisors increased its Jazz Pharmaceuticals (JAZZ) stake by 1.5% in Q2 2026, buying an estimated $11.4K and bringing the position to 3,613 shares worth $871K. The position accounts for 0.74% of the portfolio, ranked #32.

AlphaCentric Advisors first reported a position in JAZZ in Q2 2020 and has held it in 15 quarters since. The position peaked at $5.05M in Q2 2023. 646 funds tracked by Wall St. Rank hold JAZZ as of Q2 2026.

AlphaCentric Advisors held 3,613 shares of Jazz Pharmaceuticals worth $871K as of Q2 2026.
AlphaCentric Advisors bought 52 Jazz Pharmaceuticals shares in Q2 2026, an estimated $11.4K.
Jazz Pharmaceuticals made up 0.74% of AlphaCentric Advisors's portfolio in Q2 2026, its #32 holding.
AlphaCentric Advisors first reported a position in Jazz Pharmaceuticals in Q2 2020 and has held it in 15 quarters since.
AlphaCentric Advisors's Jazz Pharmaceuticals position peaked at $5.05M in Q2 2023.
646 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2026.

Based on AlphaCentric Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.